# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-25-043573
Filing Date
2025-05-01
Accepted
2025-05-01 17:20:16
Documents
5

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | tm252538d2_defa14a.htm | DEFA14A | 15820
2 | GRAPHIC | tm252538d2_defa14aimg001.jpg | GRAPHIC | 255007
3 | GRAPHIC | tm252538d2_defa14aimg002.jpg | GRAPHIC | 55812
4 | GRAPHIC | tm252538d2_defa14aimg003.jpg | GRAPHIC | 176500
5 | GRAPHIC | tm252538d2_defa14aimg004.jpg | GRAPHIC | 98392
| Complete submission text file | 0001104659-25-043573.txt |  | 816773

Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39202 | Film No.: 25904414
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)